Users Discontinuing Anti-Obesity Medications Put On Weight Far More Rapidly Compared to Dieters

A recent study indicates that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt conventional lifestyle plans.

Research printed in a major medical journal shows that while obese people frequently drop about a fifth of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such medications must be cognizant of the potential of rapid weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.

This pace of regain implies a reversion to starting weight within about 18 months.

Analyzing Treatments

The research, which examined 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.

Researchers point out that people who lose weight through diet and exercise usually have a more gradual weight regain—approximately 0.1 kg a month—once they finish.

Explaining the Quick Regain

Doctors suggest the mechanism of the drugs is key to understanding the accelerated rebound.

The injections copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making binge eating a significant risk."

A Lifelong Condition?

Health authorities advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.

Many experts argue that, considering the significant potential of weight regain, the treatment is often ongoing.

This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the long-term character of obesity," comparing it to managing conditions like diabetes.

Patient Experiences

Users who have discontinued the jabs explain a powerful resurgence of appetite.

"It was like a switch flipping and I was suddenly starving," described a patient.

This difficulty is compounded if users have not adopted permanent lifestyle or habit changes during treatment.

Growing Use

Survey data show that a significant number of adults in the UK have used these injections in the past year, with demand being substantial.

• Use is greater among women compared to males.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion access the medications through private prescriptions rather than the NHS.

Finally, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone cure and maintained weight loss likely depends on combined behavioural support.